This discovery also points to a potential new therapeutic approach, as SGLT2 inhibitors, already FDA-approved for treating type 2 diabetes, could be repurposed for treating high-grade astrocytomas. Here, SLC5A2 is linked to astrocytoma (excluding glioblastoma).